Xeris Biopharma Holdings (XERS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is XERS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth …

Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.…

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) shares hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $1…

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Fi…

Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.…

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimate…

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commerc…

Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses bas…

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commerc…

On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo…

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commer…

Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength…

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.…

Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on th…

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484 shares changed hands …

Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.…

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities rese…

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript…

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

